FUNDUSCEIN-25
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNDUSCEIN-25 is a small-molecule injectable diagnostic or therapeutic agent approved by Novartis in 1976. The specific indication and mechanism of action are unknown, but the injectable route suggests use in specialized clinical settings. The product is approaching loss of exclusivity, indicating a mature or declining phase.
LOE Approaching
Approaching loss of exclusivity signals a mature product with likely declining team investment and reduced hiring; focus shifting to generic transition or product retirement planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product is not actively hiring; roles are likely backfilled or consolidated ahead of LOE. Working on FUNDUSCEIN-25 offers legacy product experience but limited growth trajectory.
Product ManagerSales Representative
Worked on FUNDUSCEIN-25 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.